How coronavirus disease will change the face of travel medicine

Purpose of review The current article will review how the coronavirus disease 2019 pandemic has changed travel and travel medicine. Recent findings Travelers spread severe acute respiratory syndrome coronavirus 2 globally and continue to spread variants. The characteristics of the virus, the place, and time created a perfect storm that allowed the virus to quickly spread globally. The virus spread by every mode of travel with risk of transmission influenced by proximity to an infected person, duration of trip, physical characteristics of the space, and ventilation. Superspreading events were common; a small percentage of infected people accounted for most of transmission. The travel and tourist industry was devastated as lockdowns and quarantines severely restricted domestic and international travel. A trip includes multiple segments and shared sequential spaces, mostly indoors. Creating safe travel requires attention to all segments of a trip. Summary The coronavirus disease 2019 pandemic has affected every part of travel and travel medicine. The rapid development of multiple safe and effective vaccines and their deployment is allowing resumption of travel, yet many populations lack access to vaccines, and high levels of transmission continue in many areas. Providing documentation of vaccination or immunity in a consistent, verifiable, interoperable system is one of many active issues.
Source: Current Opinion in Infectious Diseases - Category: Infectious Diseases Tags: TROPICAL AND TRAVEL-ASSOCIATED DISEASES: Edited by Christina M. Coyle Source Type: research

Related Links:

Coronavirus disease 2019 (COVID-19) has resulted in a global pandemic, challenging both the medical and scientific community for the development of novel vaccines and a greater understanding of the effects of the SARS-CoV-2 virus. COVID-19 has been associated with a pronounced and out-of-control inflammatory response. Studies have sought to understand the effects of inflammatory response markers to prognosticate the disease. Herein, we aimed to review the evidence of 11 groups of systemic inflammatory markers for risk-stratifying patients and prognosticating outcomes related to COVID-19. Numerous studies have demonstrated ...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
NEW BRUNSWICK, N.J., October 21, 2021 – Johnson &Johnson (the Company) today announced that the U.S. Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP), has recommended its COVID-19 vaccine as a booster for all eligible individuals who receive an authorized COVID-19 vaccine. “Today’s recommendation supports the use of the Johnson &Johnson COVID-19 vaccine as a booster for eligible individuals in the U.S. regardless of which vaccine they initially receive,” said Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific...
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
We described a patient who developed four limb distal paraesthesia, postural instability, and facial  diplegia, ten days after vaccination with ChAdOx1 nCoV-19 (ABW1277). The electrophysiological findings were compatible with acute demyelinating motor polyneuropathy (Guillain-Barrè syndrome).DiscussionWe therefore want to describe a temporal correlation between administration of ChAdOx1 nCoV-19  (ABW1277) vaccine and GBS without evidence of other predisposing infectious or autoimmune factors. This paper aims to highlight the importance of pharmacovigilance and subsequent reports will be needed&nb...
Source: Neurological Sciences - Category: Neurology Source Type: research
Yonsei Med J. 2021 Nov;62(11):961-968. doi: 10.3349/ymj.2021.62.11.961.ABSTRACTSince the COVID-19 pandemic first began in December 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus has continuously evolved with many variants emerging across the world. These variants are categorized as the variant of interest (VOI), variant of concern (VOC), and variant under monitoring (VUM). As of September 15, 2021, there are four SARS-CoV-2 lineages designated as the VOC (alpha, beta, gamma, and delta variants). VOCs have increased transmissibility compared to the original virus, and have the potential for inc...
Source: Yonsei Medical Journal - Category: Universities & Medical Training Authors: Source Type: research
This study will provide crucial information about the efficacy and safety of the mRNA SARS-CoV-2 vaccines in HIV patients and organ transplant recipients. Furthermore, this project has the potential to pave the way for further platform trials in Switzerland.Trial registrationClinicalTrials.govNCT04805125. Registered on March 18, 2021
Source: Trials - Category: Research Source Type: clinical trials
The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in widespread morbidity and mortality, prompting the most extensive and rapid global vaccine development program in history (World Health Organization 2020a). Accelerated development and approval has been crucial to providing effective, well-tolerated vaccines against symptomatic SARS-CoV-2 infection (COVID-19). By the end of 2020, several vaccines had reached their phase 3 efficacy milestones and received emergency authorization for use (Polack et al., 2020; Baden et al., 2021; Voysey et al., 2021b; Voysey et al., 2021a).
Source: International Journal of Infectious Diseases - Category: Infectious Diseases Authors: Source Type: research
NEW BRUNSWICK, N.J., October 20, 2021 – Johnson &Johnson (NYSE: JNJ) (the Company) today announced the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for a booster dose of the Johnson &Johnson COVID-19 vaccine for adults aged 18 and older at least two months following primary vaccination with single-shot Johnson &Johnson COVID-19 vaccine; and for eligible individuals who received a different authorized or approved COVID-19 vaccine. The Johnson &Johnson booster shot will be the same formulation and dosage as the primary shot. The EUA follows a unanimous recommendat...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Latest News Source Type: news
Annu Rev Med. 2021 Oct 20. doi: 10.1146/annurev-med-042420-112725. Online ahead of print.ABSTRACTSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), emerged in China in December 2019 and quickly spread around the globe, killing more than 3 million people and causing a severe economic crisis. This extraordinary situation prompted entities in government, industry, and academia to work together at unprecedented speed to develop safe and effective vaccines. Indeed, vaccines of multiple types have been generated in record time, and many have been evaluated in clinical ...
Source: Annual Review of Medicine - Category: General Medicine Authors: Source Type: research
Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and other pathogens with pandemic potential requires safe, protective, inexpensive, and easily accessible vaccines that can be developed and manufactured rapidly at a large scale. DNA vaccines can achieve these criteria, but induction of strong immune responses has often required bulky,...
Source: Proceedings of the National Academy of Sciences - Category: Science Authors: Tags: Engineering, Immunology and Inflammation, Coronavirus (COVID-19) Biological Sciences Source Type: research
The year 2019 has seen an emergence of the novel coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing coronavirus disease of 2019 (COVID-19). Since the onset of the pandemic, biological and interdisciplinary research is being carried out across the world at a rapid pace to beat the pandemic. There is an increased need to comprehensively understand various aspects of the virus from detection to treatment options including drugs and vaccines for effective global management of the disease. In this review, we summarize the salient findings pertaining to SARS-CoV-2 biology, including symptoms, ...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
More News: Coronavirus | COVID-19 | Infectious Diseases | Pandemics | Respiratory Medicine | SARS | Vaccines